Our Team

A passionate team of scientists.

Cajal is building a research and development team with the passion, drive, and scientific expertise to execute its bold mission of generating novel disease-altering therapies for neurodegeneration.

Leadership Team

Ignacio Munoz-Sanjuan, PhD

Ignacio Munoz-Sanjuan, PhD

Chief Executive Officer

Ian Peikon, PhD

Ian Peikon, PhD

Co-Founder and Chief Scientific Officer

Andrew Dervan, MD, MBA

Andrew Dervan, MD, MBA

Co-Founder and Chief Operating Officer

Julie Harris, PhD

Julie Harris, PhD

Vice President, Preclinical Biology

Ben Logsdon, PhD

Ben Logsdon, PhD

Senior Director, Computational Biology

Team

Adebola Enikanolaiye

Adebola Enikanolaiye

Translational Models

Aishwarya Gogate

Aishwarya Gogate

Target Validation

Allison Knupp

Allison Knupp

Target Validation

Anatoly Buchin

Anatoly Buchin

Computational Biology

Anna Frolova

Anna Frolova

Finance

Anna Minkina

Anna Minkina

Computational Biology

Arsenii Pavlenko

Arsenii Pavlenko

Technology Development

Arvis Sulovari

Arvis Sulovari

Computational Biology

Ashley Bockman

Ashley Bockman

Administration

Beatriz Saldana

Beatriz Saldana

Engineering

Christian Gaetano

Christian Gaetano

Engineering

Christina Sanford

Christina Sanford

Drug Discovery

David Moore

David Moore

Facilities, EHS, & Operations

Drew Friedmann

Drew Friedmann

High Throughput Imaging

Eric Thorland

Eric Thorland

Translational Models

Eva Nachmanson

Eva Nachmanson

Finance

Felix Muerdter

Felix Muerdter

Target Validation

Hannah Hawks-Mayer

Hannah Hawks-Mayer

High Throughput Imaging

Ignas Cerniauskas

Ignas Cerniauskas

Target Validation

Jacqueline McAleer

Jacqueline McAleer

Viral Tools

Jake Gockley

Jake Gockley

Computational Biology

Jen Whitesell

Jen Whitesell

Translational Models

Jennifer Luyapan

Jennifer Luyapan

Computational Biology

Johnny Goforth

Johnny Goforth

Target Validation

Karla Hirokawa

Karla Hirokawa

Translational Models

Kat Korvas

Kat Korvas

In Vivo Sciences

Kayla Hardwick

Kayla Hardwick

Target Validation

Kyla Berry

Kyla Berry

Technology Development

Kyle Berlind

Kyle Berlind

Engineering

Luke Funk

Luke Funk

In Vitro Screens

Madison Baird

Madison Baird

Viral Tools

Marcella Cline

Marcella Cline

Drug Discovery

Michael Kuranty

Michael Kuranty

In Vivo Sciences

Molly Gasperini

Molly Gasperini

In Vitro Screens

Morgan Whelchel

Morgan Whelchel

Technology Development

Nile Graddis

Nile Graddis

Engineering

Phillip Bohn

Phillip Bohn

In Vivo Sciences

Rusty Nicovich

Rusty Nicovich

Technology Development

Sana Chintamen

Sana Chintamen

In Vitro Screens

Sarah Naylor

Sarah Naylor

Program & Alliance Management

Scott Simmons

Scott Simmons

Operations

Stephanie Dinh

Stephanie Dinh

In Vitro Screens

Thuc Nguyen

Thuc Nguyen

Target Validation

Valerie Huang

Valerie Huang

Corporate Development

Ya-Lin Lu

Ya-Lin Lu

In Vitro Screens

Board of Directors

Rob Hershberg, MD, PhD

Rob Hershberg, MD, PhD

Co-Founder and Executive Chairman, Cajal Neuroscience

Susan Hockfield, PhD

Susan Hockfield, PhD

President Emerita, Massachusetts Institute of Technology

Josh Wolfe

Josh Wolfe

Co-Founder and Managing Partner, Lux Capital

Tim Kutzkey, PhD

Tim Kutzkey, PhD

Managing Partner, The Column Group

Scientific Advisory Board

Huda Zoghbi, MD

Huda Zoghbi, MD

Co-Founder and SAB Chair

Anthony Zador, MD, PhD

Anthony Zador, MD, PhD

Co-Founder

Charles Zuker, PhD

Charles Zuker, PhD

Co-Founder

Richard Hargreaves, PhD

Richard Hargreaves, PhD

SAB Member

Jay Shendure, MD, PhD

Jay Shendure, MD, PhD

SAB Member

David Holtzman, PhD

David Holtzman, PhD

SAB Member

Martin Kampmann, PhD

Martin Kampmann, PhD

SAB Member

We are proud to be backed by a set of world-class investors

  • Lux
  • The Column Group
  • Two Sigma Ventures
  • Evotec
  • Bristol Myers Squibb
  • Alexandria
  • Dolby Family Ventures

“All outstanding work, in art as well as in science, results from immense zeal applied to a great idea.”